Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took first two doses of Vivotif in the week of 24-Nov-2025 and last two doses in the week of 01-Dec-2025; Case reference number US-BN-2025-001897 is a spontaneous case initially received from other health professional via Bavarian Nordic (reference number: CASE-000997) on 02-Dec-2025 and concerns a *26-year-old* female patient. The patient's medical history and concomitant medication details were not provided. On unknown dates, *reported as the week of 24-Nov-2025*, the patient took the first dose of Vivotif (batch number: unknown) at *a dose of one capsule, orally, for travel*. *On unknown dates, reported as the week of 24-Nov-2025*, an unknown amount of time after the first dose, the patient took the second dose of Vivotif (batch number: unknown) *at a dose of one capsule, orally. * *On unknown dates, reported as the week of 01-Dec-2025, an unknown amount of time after the second dose, also reported as a lapse in doses less than three weeks apart, the patient took the third dose of Vivotif (batch number: unknown) at a dose of one capsule, orally (explicitly coded as 'inappropriate schedule of vaccine administered') * *On unknown dates, reported as the week of 01-Dec-2025, two days after the third dose, the patient took the fourth dose of Vivotif (batch number: unknown) at a dose of one capsule, orally. * At the time of the *follow-up* report, the patient *did not experience* any adverse events due to the Vivotif vaccine. Follow-up information was received from a healthcare professional on 29-Dec-2025. New information included: vaccination dosing details, patient details, event updated from 'missed dose' to 'inappropriate schedule of vaccine administered' and confirmation that the patient did not experience any adverse events due to the Vivotif vaccine.; Reporter's Comments: A 26-year-old female patient took the third dose of Vivotif for travel, reported as a lapse in doses less than three weeks apart, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse events due to the Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 26-year-old female patient took the third dose of Vivotif for travel, reported as a lapse in doses less than three weeks apart, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse events due to the Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.